Achaogen (AKAO) priced their IPO at $12 (bottom end) and added 1M to the size to make it a total of 6M offered. The company has a promising and much-needed new antibiotic dubbed Plazomicin that can be used to treat CRE which is fatal near 1/2 the time and very hard to treat.
If all goes well this drug would be commercialized in 2018. Along the way we'll get results in 2015 and 2016 with the NDA expected in 2017. Still it's a long time to wait so this one is for patient investors.
In terms . . .